Business
IDEAYA Announces Nomination of Development Candidate, IDE397, for MAT2A Synthetic Lethality Program Targeting MTAP-Deletion Patient Population
SOUTH SAN FRANCISCO, Calif., June 8, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), an oncology-focused precision medicine company committed to
About this update from Ideaya Biosciences, Inc.
[{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., June 8, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics, announced that it has selected development candidate, IDE397, for its Methionine adenosyltransferase 2a (MAT2A) Synthetic Lethality program. The MAT2A program targets patients with tumors having methylthioadenosine phosphorylase (MTAP) deletions. With the nomination of IDE397 as a development candidate for the MAT2A program, IDEAYA has initiated IND-enabling studies and is targeting filing the Investigational New Drug (IND) application in the fourth quarter 2020.\n\n \n \n \n \n \n \n\n \n\"With IDE397, we have achieved our preclinical target product profile of a differentiated compound, including potency, safety assessment, and physicochemical property characteristics. Based on the preclinical in vivo efficacy data we have generated, we believe IDE397 has the potential for evaluation in both monotherapy and combination studies in select solid tumor types with the genetic alteration of MTAP-deletion,\" said Michael Dillon, Ph.D., Chief Scientific Officer, IDEAYA Biosciences. \nIDE397 Product Profile and MAT2A Program Summary:\nMonotherapy activity with robust tumor growth inhibition and pharmacodynamic (PD) modulation in multiple endogenous MTAP-/- in vivo models Monotherapy activity and tumor regression in HCT116 MTAP-/- xenograft model No changes in liver enzymes or increased unconjugated bilirubin levels observed in preclinical studies Favorable physicochemical properties and pharmacokinetics observed across multiple species MAT2A program enabled by structure-based drug design; over 17 high resolution co-crystal structures have been resolved to enable lead optimizationAbout MAT2A and MTAP-Deletion: MTAP-null cells lack the ability to metabolize 5-methylthioadenosine, or MTA, which is an essential step in a biochemical pathway involved in salvaging metabolite S-adenosyl methionine, or SAM. Increased levels of MTA partially inhibit the methyltransferase PRMT5 for which SAM is the substrate. This partial inhibition renders MTAP-null cells more dependent on the activity of methionine adenosyltransferase II alpha or MAT2A, an enzyme that is responsible for the...